GlassScriptPhysician profile
Adam Lewis
NPI 1891134219
$1,794.11
in general payments reported to CMS, 2019-2025
18 companies · $885 in 2025
The $885 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.09 · 2023: $178 · 2024: $679 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.02 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $321.65 | 2019-2025 | Tysabri, Vumerity |
| Lilly USA, LLC | $261.34 | 2024-2025 | Kisunla, Amyvid |
| Genzyme Corporation | $246.20 | 2019-2024 | |
| Amgen INC. | $185.56 | 2024-2025 | Uplizna |
| Abbvie INC. | $167.27 | 2023-2025 | |
| Ucb, INC. | $136.36 | 2025 | Nayzilam |
| Lundbeck LLC | $88.23 | 2023-2025 | Vyepti |
| Argenx US, INC. | $70.76 | 2024-2025 | Vyvgart Hytrulo |
| Eisai INC. | $65.19 | 2025 | |
| Vanda Pharmaceuticals INC. | $60.23 | 2024 | Ponvory |
| Pfizer INC. | $37.72 | 2025 | |
| Neurelis, INC. | $32.72 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $25.65 | 2024 | Xeomin |
| Insightec,INC | $23.64 | 2025 | Exablate |
| Axsome Therapeutics, INC. | $21.18 | 2025 | Symbravo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $19.71 | 2024 | |
| Dynasplint Systems INC. | $16.70 | 2024 | Dynasplint |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.